Alfasigma Enters Licensing Agreement for Linerixibat With GSK

AI Briefing

• – Alfasigma enters licensing agreement with GSK for Linerixibat
• – DLA Piper advises Alfasigma on deal
• – Linerixibat is an investigational therapy